Milton C. Ault III - Jan 31, 2024 Form 4 Insider Report for Alzamend Neuro, Inc. (ALZN)

Role
Director, 10%+ Owner
Signature
/s/ Milton C. Ault, III
Stock symbol
ALZN
Transactions as of
Jan 31, 2024
Transactions value $
-$1,220,000
Form type
4
Date filed
2/2/2024, 04:30 PM
Previous filing
Apr 19, 2024
Next filing
Mar 1, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALZN Series A Convertible Preferred Stock Purchase -$1.22M -1.22K -50% $1,000.00* 1.22K Jan 31, 2024 Common Stock 1.22M $1.00 By Ault Life Sciences Fund, LLC F1, F2, F3
transaction ALZN Warrants Purchase $0 -1.22M -50% $0.00 1.22M Jan 31, 2024 Common Stock 1.22M $1.20 By Ault Life Sciences Fund, LLC F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of series A convertible preferred stock (the "Series A Convertible Preferred Stock") have no expiration date.
F2 Each share of Series A Convertible Preferred Stock has a stated value of $1,000 (the "Stated Value") and is convertible into a number of shares of common stock determined by dividing the Stated Value by the conversion price, which is currently $1.00.
F3 Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Ault Alliance, Inc. ("AAI"). Mr. Ault, the Executive Chairman of AAI, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
F4 These warrants were issued for no additional consideration in connection with the purchase of the Series A Convertible Preferred Stock.